- The experimental oral therapeutic is termed as MK-4482
- It is currently in phase two trials
Merck has scheduled very large pivotal studies as early as September. It is for its oral coronavirus treatment. It is in collaboration with Ridgeback Biotherapeutics. The statement came on Friday by a company executive.
Dr. Roger Perlmutter said that these studies are go....
Tags : Merck, Corona Virus pandemic, COVID - 19, Corona Virus treatment, Corona Virus Vaccine,